University of Charleston
Tamer Fandy
Contact Info


Chair, Department of Pharmaceutical and Administrative Sciences

  • Postdoctoral fellow, hematologic malignancies, Johns Hopkins University
  • Ph.D., Department of Pharmaceutical Sciences, University of Maryland
  • M.Sc., Department of Pharmaceutical Sciences, University of Southern California
  • B.S., Pharmacy and Pharmaceutical Sciences, Cairo University

My laboratory focuses on both basic and translational research in the field of molecular epigenetics and experimental therapeutics. I am interested in dissecting the molecular changes associated with drugs that target the epigenome (epigenetic modifiers) and how these changes contribute to their antitumor effect. Current projects in the lab include:

  1. Genome wide DNA methylation and histone modifications profiling in hematologic malignancies.
  2. Development of DNA methylation inhibitors.
  3. Development of rational combinations of epigenetic modifiers as antitumor agents.
  4. Investigating the potential of dietary agents that target the epigenome in cancer chemoprevention and therapy.

Selected Publications

For a complete list of publications,

  1. Hedrich WD, Fandy TE, Ashour HM, Wang H, Hassan HE (2018). Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned. Clin Pharmacokinet. 2018 Jun;57(6):687-703
  2. Gunasekara DC, Zheng MM, Mojtahed T, Woods, JR, Fandy TE, Riofski MV, Glackin CA, Hassan HE, Krishner J, Colby DA (2016). 15-Methylene-Eburnamonine Kills Leukemic Stem Cells and Reduces Engraftment in a Humanized Bone Marrow Xenograft Mouse Model of Leukemia. ChemMedChem 2016 Nov 7;11(21):2392-2397.
  3. Hassan H, Keita J-A, Narayan L, Brady S, Fredrick R, Carlson S, Glass K, Buttolph T, Fandy TE (2016). The combination of dimethoxycurcumin with DNA methylation inhibitor enhances gene re-expression of tumor suppressor genes and antagonizes their cytotoxic effect. Epigenetics Sep 2:1-10.
  4. Fandy TE, Abdullah I, Khayat M, Colby D, Hassan H (2016). In vitro Characterization of Transport and Metabolism of the Alkaloids; Vincamine, Vinpocetine and Eburnamonine. Cancer Chemother and Pharmacol 77(2):259-67.
  5. Hassan H, Carlson S, Abdallah I, Buttolph T, Glass KC, Fandy TE (2015). Curcumin and dimethoxycurcumin induced epigenetic changes in leukemia cells. Pharm Res. 32(3):863-75.
  6. Fandy TE. Jiemjit A, Thakar M, Rhoden P, Suarez L, Gore SD (2014). Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. Clin Cancer Res. 20(5):1249-58.
  7. Fandy, TE (2012). The sequential combination paradigm in epigenetic therapy. J Pharmacogenom Pharmacoproteomics 3: e124. doi:10.4172/2153-0645.1000e124
  8. Fandy TE, Gore SD (2010). Epigenetic targets in human neoplasms. Epigenomics 2(2): 221-232.
  9. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, et al. (2009). Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114(13): 2764-2773.
  10. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, et al. (2009). MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114(16): 3448-3458.
  11.  Fandy TE (2009). Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem 16(17): 2075-2085.
  12.  Jiemjit A*, Fandy TE*, Carraway H, Bailey KA, Baylin S, Herman JG, et al. (2008). p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 27(25): 3615-3623. *Both authors contributed equally to the work.
  13. Takebe N, Cheng X, Fandy TE, Srivastava RK, Wu S, Shankar S, et al. (2006). IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther 5(2): 457-466.
  14. Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK (2005). Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7(7): 646-657.

  • Soccer & Swimming
  • Music